Form 4: Corcept CFO Granted 140,000 Stock Options

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, was granted 140,000 stock options with an exercise price of $35.70.

Summary

• Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (CORT), was granted 140,000 stock options.
• The options have an exercise price of $35.70 per share.
• The earliest transaction date for these options is February 27, 2026.
• The options will vest ratably in equal installments on each monthly anniversary of February 27, 2026, over a four-year period.
• Vesting is contingent upon Mr. Mokari's continued service through each vesting date.
• The expiration date for these stock options is February 27, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard executive compensation event, aligning the CFO's interests with long-term company performance, which is generally a positive signal for corporate governance and executive retention.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term incentives with shareholder value creation.
• This is a standard form of executive compensation, indicating continued commitment to retaining key management.

Future Outlook

The stock options are subject to a four-year vesting schedule, indicating a long-term incentive structure tied to the Chief Financial Officer's continued service with the company.

Industry Context

StockSavvy.ai notes that stock option grants are a common and widely accepted form of executive compensation in the biotechnology and pharmaceutical industries. This practice aims to align management incentives with the long-term performance and shareholder value creation of the company, a standard approach for retaining and motivating key executives.

Comparison to Industry Standards

• StockSavvy.ai notes that an option grant of 140,000 shares to a Chief Financial Officer is within the typical range for mid-to-large cap biotechnology companies, comparable to grants observed at peers such as BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc. This size of grant is generally considered competitive for attracting and retaining executive talent in the sector.

Related Party Transactions

• The grant of stock options to the Chief Financial Officer constitutes a related party transaction, which is a standard component of executive compensation packages.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from aligned management incentives for long-term growth.
• Employees (specifically CFO): Direct financial benefit and incentive for continued service and performance.

Next Steps

• The stock options will vest ratably over a four-year period, contingent on the Chief Financial Officer's continued service.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a key executive, which is a standard compensation practice. It does not provide new information that would significantly alter the investment thesis for Corcept Therapeutics, thus a 'hold' recommendation remains appropriate.

Keywords

Corcept Therapeutics, CORT, Stock Options, Executive Compensation, Insider Transaction, Atabak Mokari, CFO, Form 4